As of May 2024, we are delighted that AxTalis and MAP have joined forces to create a new group focussing on accelerating patient access across European markets.
Bringing your treatments to patients can be a long and complicated journey with significant financial investment. This is especially challenging for innovative technologies. Our expertise gives your products the best chance of reaching patients sooner. MAP understands the challenges facing BioPharma companies in bringing their products to market and helps clients navigate the complexities of market access in the UK and Europe. Our cross-functional team has completed over 200 successful HTA submissions, drawing on profound expertise from diverse sectors including industry, HTA and payer organisations, healthcare, academia and consultancy.
Assess the appropriateness of clinical trials for the UK and European markets
Early economic modelling
Target Product Profile testing
Review comparators and Health-Related Quality of Life inputs and outputs
Engage with clinicians to confirm treatment pathways and product positioning
Facilitate early dialogue with payers and Patient Advocacy Groups
Organise and run advisory boards and Delphi panels of Key Opinion Leaders
Support marketing strategy
Develop the UK and European value propositions
Advise and support pricing strategy
Develop market access strategies based on over 200+ successful products brought to market
Develop your optimum evidence package by providing early insights and strategy
With launch sequencing through international reference pricing
Obtain payer and stakeholder insights into the perceived value of your product
Understand payer evidence requirements to support reimbursement
Test the willingness to pay through payer research
With commercial access pricing support to enhance reimbursement
Cost effectiveness and budget impact modelling
Early model review
Disease area and payer landscape insights research
Evidence gap analysis and mitigation plans
Treatment pathway and model input validation
KOL engagement advisory boards
Evidence generation support
Stakeholder engagement and payer negotiations
Guidance on pricing strategies
HTA modelling
Building models for you from scratch or repurposing existing models
Strategic planning, positioning and message development
Political, economic, social and technological analysis to help strategic and operational business planning
Bespoke policy analysis to identify opportunities and risks, advisory boards to provide clinical and stakeholder insights
Tailored monitoring of policy and stakeholder developments
Influencing policy through reports, consultation responses and briefings
Evidence-based thought leadership and collaborative policy development
Stakeholder mapping and prioritisation based on relevance and influence
Stakeholder engagement, political and media communications
Organising and attending roundtables, seminars, conferences and parliamentary events
Policy and Public Affairs training
PIM and EAMS applications
Value propositions
Global value dossiers
Systematic literature reviews
HTA and reimbursement submissions
Study reports
Delphi panels to achieve consensus on issues contributing to submissions
Stakeholder communication tools
Publications
Strategic contract review services with the aim of protecting clients’ interests
Counselling key stakeholders to ensure compliance with relevant national and international healthcare laws, regulations, and guidance
Strategic legal support during the process of NICE and other Market Access submissions across the UK and Europe
Partnering with MAP internal functions to ensure a holistic approach to clients’ Market Access needs while assessing and mitigating compliance risks
Leveraging knowledge of emerging legal and industry issues and trends to inform bespoke legal support
Ensuring in-house compliance to regulatory codes by providing training and guidance
Rich Expertise: With over 300 years of combined experience across European markets, our team brings profound expertise from diverse sectors including industry, HTA and payer organisations, healthcare, academia, and consultancy.
Matrix Approach: We tackle challenges from multiple perspectives, ensuring a holistic view by involving various functions in the decision-making process, thus connecting all the dots.
Joined-up Services: Our comprehensive services cover the entire product lifecycle, from regulatory application to reimbursement, ensuring seamless support at every stage.
Power of our Network: Our extensive network, encompassing a wide range of stakeholders, grants us access to insights informing an optimal market access launch in Europe.
Tailored Approach: We offer expert consultancy paired with digital solutions, customised to your unique circumstances, to help get your products from the lab to patients as smoothly and quickly as possible.
We pride ourselves to have a personal relationship with our network of stakeholders, opinion leaders and clients, and we would love to get to know you as well. Feel free to reach out for a chat.
Arthur Vanlaethemstraat 1
9050 Gentbrugge
Belgium
BE0745.587.926
RPR Gent afdeling Gent
Supervising authority for pharmacovigilance: FAMHP
(ADR@fagg.be)
© 2024 Medical Affairs, Market Access and Regulatory Compliance | Privacy Policy | Cookie Policy